Boryung eying sales of 10 billion won with new drug

Boryung Pharmaceutical Co. says its new drug for hypertension “Kanarb (fimasartan)”, angiotensin II receptor antagonist with a selective AT1 receptor blockade effect, is expected to achieve a 10 billion won in sales within one year since its launch in March.

Such robust sales will be possible due to robust demand from general hospitals, the company said.

Fimasartan showed its excellent ef...